Burns Matteson Capital Management LLC Has $424,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Burns Matteson Capital Management LLC reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,170 shares of the life sciences company’s stock after selling 185 shares during the quarter. Burns Matteson Capital Management LLC’s holdings in Illumina were worth $424,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Zacks Investment Management bought a new position in shares of Illumina in the third quarter valued at about $2,924,000. Freemont Management S.A. bought a new position in shares of Illumina in the third quarter worth about $1,565,000. Assenagon Asset Management S.A. lifted its position in shares of Illumina by 5.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock worth $5,712,000 after purchasing an additional 2,338 shares in the last quarter. CCLA Investment Management grew its stake in shares of Illumina by 20.5% during the fourth quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock valued at $71,493,000 after purchasing an additional 91,122 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Illumina by 65.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock valued at $4,278,000 after purchasing an additional 12,986 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 9.6 %

Shares of ILMN stock opened at $111.06 on Monday. The company has a market capitalization of $17.61 billion, a price-to-earnings ratio of -14.46 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The firm has a fifty day moving average of $136.70 and a 200-day moving average of $135.43.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. As a group, equities research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ILMN. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Leerink Partners upped their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a research note on Friday. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $161.40.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.